Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- TakedaTakeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia VeraCompanies: Takeda Pharmaceutical CompanyOSAKA, Japan & CAMBRIDGE, Mass., August 28, 2026--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
- Robbins LLPRobbins LLP Urges AARD Stockholders Who Lost Money Investing in Aardvark Therapeutics, Inc. to Contact the Firm for Information About Leading the Class ActionShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's...
- Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress
- Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateOragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status.
- Nektar TherapeuticsNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common...
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of August 27, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences ConferenceNurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City.
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 43 / 2026
- Best Stem Cell Center India: Advanced Regenerative Medicine for International PatientsIndia is emerging as a destination for international patients seeking stem cell therapy. Reputable centers focus on experienced specialists, personalized care, modern facilities, patient safety, transparency, and comprehensive international support.
- Robbins Geller Rudman & Dowd LLP1 MONTH CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 DeadlineRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September...
- CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-